Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis

References

• GBD. 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–1922. doi: 10.1016/S0140-6736(18)32335-3
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Y, He Q. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China. Health Econ Rev. 2022;12(1):66–75. doi: 10.1186/s13561-022-00410-x
   PubMed Web of Science ®Google Scholar
• Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2020;9(5):1770–1784. doi: 10.21037/tlcr-19-605
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527. doi: 10.1200/JCO.19.00934
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3
   PubMed Web of Science ®Google Scholar
• Keating GM. Nivolumab: a review in advanced squamous non-small cell lung cancer. Drugs. 2015;75(16):1925–1934. doi: 10.1007/s40265-015-0492-9
   PubMed Web of Science ®Google Scholar
• CSCO. Guidelines of Chinese Society of Clinical Oncology (CSCO) non-small cell lung cancer. Beijing: People’s Medical Publishing House; 2020.
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi: 10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492. doi: 10.18632/oncotarget.2980
   PubMedGoogle Scholar
• Liu X, Yi Y. Recent updates on sintilimab in solid tumor immunotherapy. Biomark Res. 2020;8(1):69–77. doi: 10.1186/s40364-020-00250-z
   PubMed Web of Science ®Google Scholar
• Shi Y, Wu L, Yu X, et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond). 2022;42(12):1314–1330. doi: 10.1002/cac2.12385.
   PubMed Web of Science ®Google Scholar
• Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2(1):19–21. doi: 10.1001/jamaoncol.2015.4191
   PubMed Web of Science ®Google Scholar
• Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020.
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528. doi: 10.1111/j.1524-4733.2004.75003.x
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9–21. doi: 10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Soft. 2016;70(8):i08–45. doi: 10.18637/jss.v070.i08
   PubMed Web of Science ®Google Scholar
• Chen P, Wang X, Zhu S, et al. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC. Front Public Health. 2022;10:956792–956802. doi: 10.3389/fpubh.2022.956792
   PubMed Web of Science ®Google Scholar
• Zhu C, XX X, Wu B, et al. Cost-effectiveness analysis of camrelizumab plus chemotherapy vs. chemotherapy alone as the first-line treatment in patients with IIIB-IV non-squamous non-small cell lung cancer (NSCLC) without EGFR and ALK alteration from a perspective of health-care system in China. Front Pharmacol. 2021;12:735536–735546. doi: 10.3389/fphar.2021.735536
   PubMed Web of Science ®Google Scholar
• Rui M, Fei Z, Wang Y, et al. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. J Med Econ. 2022;25(1):618–629. doi: 10.1080/13696998.2022.2071066
   PubMed Web of Science ®Google Scholar
• Ilson DH, van Hillegersberg R. Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology. 2018;154(2):437–451. doi: 10.1053/j.gastro.2017.09.048
   PubMed Web of Science ®Google Scholar
• Ye ZM, Xu Z, Zeng FY, et al. Cost-effectiveness analysis of sintilimab combined with chemotherapy versus chemotherapy alone as the first-line treatment for advanced esophageal cancer. Front Pharmacol. 2022;13:934275–934283. doi: 10.3389/fphar.2022.934275
   PubMed Web of Science ®Google Scholar
• Shao T, Zhao M, Tang W. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma. Front Oncol. 2022;12:953671–953679. doi: 10.3389/fonc.2022.953671
   PubMed Web of Science ®Google Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–644. doi: 10.3111/13696998.2016.1151432
   PubMed Web of Science ®Google Scholar
• Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2):e210037–47. doi: 10.1001/jamanetworkopen.2021.0037
   PubMed Web of Science ®Google Scholar
• Peng Y, Zeng X, Peng L, et al. Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13:778505–778511. doi: 10.3389/fphar.2022.778505
   PubMed Web of Science ®Google Scholar
• Gu X, Zhang Q, Chu YB, et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89. doi: 10.1016/j.lungcan.2018.11.029
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989X12458348.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice? Recenti Prog Med. 2019;110(3):138–143. doi: 10.1701/3132.31141
   PubMedGoogle Scholar
• Giuliani J, Bonetti A. Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs. Clin Lung Cancer. 2017;18(5):e363–5. doi: 10.1016/j.cllc.2017.04.007
   PubMed Web of Science ®Google Scholar
• Gao L, Li SC. Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and Markov models. Appl Health Econ Health Policy. 2019;17(3):371–380. doi: 10.1007/s40258-018-0452-0
   PubMed Web of Science ®Google Scholar
• Shao T, Ren Y, Zhao M, et al. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China. Front Public Health. 2022;10:912921–912932. doi: 10.3389/fpubh.2022.912921
   PubMed Web of Science ®Google Scholar